In the subgroup of patients not receiving SGLT-2 inhibitors at baseline, semaglutide was associated with a statistically significant reduction in risk of the primary endpoint of 27% (hazard ratio 0.73, 95% confidence interval 0.630.85)
If GLP-1 weight loss injections like tirzepatide (Zepbound, Mounjaro) are already doing their job, switching isn't automatically an upgrade
Travel (AbbVie, EssilorLuxottica, European Alliance of Associations for Rheumatology)
BAT-specific disruption of ERAD results in abnormal mitochondrial morphology, impaired heat production, and increased cold sensitivity, highlighting the importance of ERAD in adaptive thermogenesis
While theres debate about how it works, the addition of GIP in this case may be increasing the effectiveness of GLP-1, creating an added weight loss effect
Join our mailing list to stay up to date on whats happening at NurseCE4Less and make sure you never miss a deadline!